PaxMedica Appoints David Hough M.D. as Chief Medical Officer
Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire...
Neuroscience
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
The 7,380,394 AEON shares reflected in the Form 4 filed on August 14th were transferred to limited partners of Strathspey Crown Strathspey Crown did...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for...
Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform
New automated features elevate the standard of care for NeuroStar® Advanced Therapy practicesMALVERN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) --...
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the...
Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results
MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology...
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2...
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in...
New Study Finds That Masimo SedLine® Patient State Index (PSi) Has the Potential to Improve Brain Monitoring for Patients Sedated with Dexmedetomidine
Masimo PSi, a Processed EEG Parameter, “Better Captured” Changes in Brain State Compared to Other Assessment MethodsIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ:...
Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies
MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced...
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers...
Cognetivity Neurosciences Announces Successful Registration With Health Canada for Clinical use of CognICA(TM) AI-Powered Brain Health Technology in Canada
Approval opens up a new major market for CognICA, providing a solution to the urgent requirement for large-scale early detection...
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
-A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) --...
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,...
BrainsWay to Report Second Quarter 2023 Financial Results on August 9, 2023
BURLINGTON, Mass. and JERUSALEM, July 26, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Kincell Bio Launches with $36M to Make Cell Therapy Development and Manufacturing Accessible for Early-Stage Innovators
Cell therapy CDMO spins out of Inceptor Bio to help innovators develop and manufacture life-saving cell therapies Kincell to be...
AC Immune SA Appoints New Chief Medical Officer
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee memberLausanne,...
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols...
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
Linda Burkly Editas Medicine today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and...
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in...